<DOC>
	<DOCNO>NCT00817362</DOCNO>
	<brief_summary>The purpose study see IPI-504 combination trastuzamab effective treatment HER2 positive metastatic breast cancer</brief_summary>
	<brief_title>Efficacy Safety IPI-504 With Trastuzumab Pretreated , Locally Advanced Metastatic HER2 Positive Breast Cancer</brief_title>
	<detailed_description>Recent clinical data demonstrate even heavily pretreated patient trastuzumab-refractory HER-2 positive breast cancer , target HER2 efficacious . IPI-504 HSP90 inhibitor chemically related 17-AAG study clinical trial combination trastuzamab response rate 26 % ( 7/27 ) demonstrate patient pretreated , HER2-positive breast cancer . These data provide strong scientific rationale clinical test IPI-504 plus trastuzumab patient pretreated , locally advanced metastatic HER2-positive breast cancer</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Locally advanced/metastatic breast cancer . HER2expressing primary metastatic tumor Two prior regimen HER2 . Trastuzumab must give . No limit prior therapies Measurable disease RECIST 1.1 Clinical progression LVEF WNL ECOG 0 1 Last dose chemotherapy , radiotherapy , surgery , ablative therapy , tyrosine kinase inhibitor , ≥2 week Administration biological therapy ≥4 week Last dose trastuzumab must ≥1 , ≥3 week prior start , previously administer every 3 week schedule . Resolution toxic effect baseline Grade 1 , except alopecia ( NCI CTCAE Version 3.0 Organ marrow function : Hemoglobin ≥8.0 g/dL ANC ≥1200/µL Platelets ≥75,000 /µL ALT AST ≤ 1.5 x ULN Alkaline phosphatase ≤2.5 x ULN , ≤3.0 x ULN secondary liver metastasis . Serum bilirubin WNL Serum albumin ≥3.0 g/dL PT , PTT ≤1.5 x ULN Serum creatinine ≤1.5 x ULN Negative pregnancy test Prior treatment Hsp90 inhibitor . Grade 4 AE secondary trastuzumab . Grade 3/4 infusion reaction Grade 3/4 symptomatic heart failure Medication/food CYP3A inhibitor inducer . Hx 6 month : cardiac disease acute coronary syndrome unstable angina , symptomatic congestive heart failure , uncontrolled hypertension , cirrhotic liver disease , cerebrovascular accident significant comorbid condition Grade 3 4 hemorrhagic event within 6 month . HIV positivity Baseline QT correct , QTcF &gt; 470 m Sinus bradycardia &lt; 50 bpm Secondary pharmacologic therapy may enroll stop therapy normalizes heart rate . Malignancies within 3 year nonmelanomatous skin cancer , nonmuscleinvasive bladder cancer carcinoma situ cervix . Active keratitis keratoconjunctivitis Active brain metastasis ( e.g. , require therapy steroid radiation therapy ; intracranial progression 4 week completion radiation therapy ) uncontrolled seizure disorder , ongoing spinal cord compression , carcinomatous meningitis . If clinically stable brain metastasis ( previously treat untreated ) present pt eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>HER2 Positive Breast Cancer</keyword>
	<keyword>Cancer breast</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Herceptin</keyword>
</DOC>